Retrospective evaluation of epidemiological and clinical data of patients diagnosed with vitiligo in our outpatient clinic
1 Department of Dermatology, Turgutlu State Hospital, Manisa, Turkey.
2 Department of Dermatology, Izmir Katip Çelebi University, Medical Faculty, Atatürk Research and Education Hospital, Izmir, Turkey.
Research Article
World Journal of Advanced Research and Reviews, 2024, 21(01), 1844–1850
Article DOI: 10.30574/wjarr.2024.21.1.0208
Publication history:
Received on 07 December 2023; revised on 15 January 2024; accepted on 17 January 2024
Abstract:
Objective: It was aimed to evaluate retrospectively the epidemiological and clinical data of patients who applied to our clinic and were diagnosed with vitiligo. Epidemiological and clinical evaluation guide the progression, choice of treatment, and diagnosis of the comorbidities of the disease.
Methods: 327 patients evaluated as non-segmental vitiligo were included in the study. Demographic characteristics of the patients (age and gender), age at onset of vitiligo, treatments used for vitiligo, clinical type of vitiligo, location of lesions, and accompanying autoimmune thyroid disease data were evaluated.
Results: Of 327 patients, 169 (51.7%) were male and 158 (48.3%) were female. The male/female ratio was found to be 1,1:1. The mean age of the patients was 37.26±18.07 years, and the mean age according to gender was 37.44±18.19 years in females and 37.08±18 years in males. The mean age of onset of the disease was 29.17±15.79 years, and the mean age of onset by gender was 29.13±16.46 years in females and 29.2±15.15 years in males. Regarding onset of the disease, 54% of the patients were <30 years old, and 46% of the patients were 30 years or older. Generalized vitiligo (58.8%) and acrofacial vitiligo (29.9%) were the most common clinical types. Head and neck (68.9%) and extremities (64%) were the most common locations of the lesions. Concomitant autoimmune thyroid disease was seen in 13.5% of the patients. Accompanying autoimmune thyroid disease according to gender was 19.5% in females and 7.4% in males, and there was a statistically significant difference between the groups. It was observed that 89.5% of the patients received treatment for vitiligo, and 10.5% did not receive any treatment. The most commonly used treatments were found to be topical treatment (76.1%) and topical treatment+phototherapy (14.6%).
Conclusion: The epidemiological and clinical characteristics of the patients in our study were similar to other studies in the literature. Concerning the highest prevalence of generalized vitiligo in our study, phototherapy and/or systemic therapy use should have been considered when their use was indicated, and factors precluding their more widespread use could be investigated in other studies.
Keywords:
Vitiligo; Epidemiology; Autoimmune Thyroid Disease; Vitiligo Treatment.
Full text article in PDF:
Copyright information:
Copyright © 2024 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0